NMCC Clinical Trials: Recruiting
The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.
| Category | Trial ID | Org | Description Official Title / (Optional) Comment / ClinicalTrials.gov link |
Trial Status | Opened
Updated |
|---|---|---|---|---|---|
| Breast Adjuvant | Alliance A011502 | NMCCA |
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 4 May 2017
29 Mar 2018 |
| Breast Adjuvant | Alliance A221505 | NMCCA |
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction Radiation CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 30 Jan 2018
6 Sep 2018 |
| Breast Adjuvant | Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-0 (PALLAS) | NMCCA |
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 31 Jul 2015
3 Sep 2018 |
| Breast Adjuvant | ECOG-ACRIN EA1131 | NMCCA |
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 29 Jul 2016
29 Mar 2018 |
| Breast Adjuvant | NSABP B51/RTOG 1304 | NMCCA |
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Radiation CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 7 Jun 2013
16 May 2017 |
| Breast Adjuvant | SWOG S1207 | NMCCA |
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 28 Aug 2012
31 Aug 2018 |
| Breast Adjuvant | SWOG S1418/BR006 | NMCCA |
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 4 Nov 2016
16 Nov 2018 |
| Breast Advanced | Alliance Foundation Trials AFT-38 | NMCCA |
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer Metastatic, First Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 28 Oct 2016
19 Jun 2018 |
| Breast Advanced | ECOG E2112 | NMCCA |
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer Metastatic, Second-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 16 Apr 2014
23 Oct 2018 |
| Breast Advanced | Macrogenics, Inc. CP-MGAH22-04 | NMCCA |
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment Metastatic, Second-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 9 Jul 2015
18 Oct 2018 |
| Breast Advanced | NRG-BR002 | NMCCA |
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Metastatic, First Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 18 Feb 2015
5 Nov 2018 |
| Breast Advanced | ODO-TE-B301 | NMCCA |
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane Metastatic, First-Line & Second-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 31 Oct 2017
2 Nov 2018 |
| Breast Advanced | SWOG S1416 | NMCCA |
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Metastatic, First-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 5 Nov 2015
16 Nov 2018 |
| Breast Neoadjuvant | Alliance A011106 | NMCCA |
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study ER+, HER2-. Enrolling in ARM 1, Anastrozole only. CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 1 Oct 2013
6 Sep 2018 |
| GI Colorectal Adjuvant | SWOG S0820 | NMCCA |
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 9 May 2011
31 Aug 2018 |
| GI Colorectal Advanced | Canstem 303C | NMCCA |
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Metastatic, Second-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 27 Apr 2016
15 Oct 2018 |
| GI Colorectal Advanced | SWOG S1613 | NMCCA |
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification Metastatic, Second-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 7 Dec 2017
31 Aug 2018 |
| GI Non-Specific | Astellas/8951-CL-0302 | PCR |
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 31 Aug 2018
16 Nov 2018 |
| GI Pancreatic Advanced | Canstem 111P | NMCCA |
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Metastatic, First-Line CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 15 Dec 2016
5 Nov 2018 |
| GU Non-Specific | Immu-132-06 | PCR |
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 6 Jun 2018
9 Nov 2018 |
| GU Prostate Adjuvant | Advantagene PrTK03 | NMCCA |
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 20 Sep 2011
14 Nov 2018 |
| GU Prostate Adjuvant | NRG-GU005 | NMCCA |
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 11 Dec 2017
6 Nov 2018 |
| GU Prostate Advanced | Alliance AFT-19 | NMCCA |
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Post-Prostatectomy CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 4 Jan 2017
5 Sep 2018 |
| GU Prostate Metastatic | VISION 177Lu-PSMA-617 / PCR Trial | PCR |
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 30 Apr 2018
15 Nov 2018 |
| Head And Neck Adjuvant | ECOG-ACRIN EA3132 | NMCCA |
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 12 Apr 2016
2 Aug 2018 |
| Hematology – See: Blood | |||||
| Ill Defined | SWOG S1609 | NMCCA |
SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 15 Jul 2016
16 Nov 2018 |
| Leukemia – SEE: blood | |||||
| Lung NSCLC Adjuvant | Alliance A081105 | NMCCA |
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 17 Jul 2014
16 Nov 2018 |
| Lung NSCLC Adjuvant | Alliance A151216 | NMCCA |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 18 Jul 2014
16 Nov 2018 |
| Lung NSCLC Adjuvant | ECOG-ACRIN E4512 | NMCCA |
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 28 Jul 2014
11 Dec 2017 |
| Lung NSCLC Advanced | BMS CA209568 | NMCCA |
A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 9 May 2017
29 Mar 2018 |
| Lung NSCLC Advanced | SWOG S1403 | NMCCA |
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 8 May 2015
10 Apr 2018 |
| Lung Other | SWOG S1400 | NMCCA |
Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 13 Feb 2017
|
| Lung SCLC Advanced | SWOG S1400G | NMCCA |
A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 19 Dec 2017
31 Aug 2018 |
| Lung SCLC Advanced | SWOG S1400I | NMCCA |
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) CinicalTrials.gov – Details and eligibility criteria |
Recruiting | 30 May 2016
31 Aug 2018 |
| Molecular Genetics | INST 96144 City of Hope | NMCCA |
Molecular Genetics Studies of Cancer Patients and Their Relatives Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 9 Dec 2014
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-A | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-B | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-C1 | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-C2 | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-E | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-J | NMCCA |
Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-L | NMCCA |
Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-M | NMCCA |
Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
20 Nov 2018 |
| Mutation Based | ECOG-ACRIN EAY131-S2 | NMCCA |
Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-T | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-U | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-V | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-W | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-X | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Y | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1A | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1B | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1C | NMCCA |
Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1D | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1E | NMCCA |
LOXO-101 in Patients with Tumors with NTRK Fusions Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
29 Mar 2018 |
| Mutation Based | ECOG-ACRIN EAY131-Z1I | NMCCA |
Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 11 Mar 2017
29 Mar 2018 |
| Pancreatic – SEE: GI Pancreatic | |||||
| Prostate (all stages) – SEE: GU Prostate | |||||
| Skin Melanoma Advanced | ECOG-ACRIN EA6134 | NMCCA |
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 26 Apr 2017
17 Nov 2018 |
| Solid Tumors Other | ECOG-ACRIN EAY131-F | NMCCA |
Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Solid Tumors Other | ECOG-ACRIN EAY131-G | NMCCA |
Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Solid Tumors Other | ECOG-ACRIN EAY131-H | NMCCA |
Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer) Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
| Solid Tumors Other | ECOG-ACRIN EAY131-R | NMCCA |
Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations Unable to find this clinical trial listed on ClinicalTrials.gov |
Recruiting | 5 Nov 2016
29 Mar 2018 |
TRIAL STATS: Recruiting Only, Total = 61 |